| Cat. No. |
Product Name |
Information |
| PC-35756 |
LY3295668
|
LY3295668 (LY-3295668, AK-01) is a novel potent, highly selective, orally active Aurora-A kinase inhibitor with Ki of 0.8 nM, H446 AurA auto-P IC50 of 0.6 nM. |
| PC-62560 |
AS 703569
|
Cenisertib (AS 703569;R763) is a novel potent, orally available inhibitor of Aurora kinases, exhibits signifficant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo (A549 EC50=9 nM). |
| PC-42409 |
Tozasertib
|
Tozasertib (MK-0457, VX-680) is a highly potent, selective and reversible Aurora kinase inhibitor with Ki of 0.6, 18 and 4.6 nM for Aurora A, B and C, respectively. |
| PC-20713 |
LXY18
|
LXY18 is a potent orally available blocker of AURKB relocation in mitosis with minimum effective concentration (MEC) of 3.5 nM for inducing polyploidy, shows broad-spectrum growth inhibitory and apoptosis-inducing activities with low nanomolar potencies. |
| PC-49273 |
PF-03814735
|
PF-03814735 is a potent, orally bioavailable, reversible inhibitor of both Aurora A and Aurora B kinases with IC50 values of 0.8 and 5 nM, respectively. |
| PC-38795 |
PHA-680626
|
PHA-680626 is a kinase inhibitor exhibiting strong inhibitory activity on both Bcr-Abl and Aurora kinases, also inhibits the formation of the Aurora-A/N-Myc complex. |
| PC-73448 |
Tinengotinib
|
Tinengotinib (TT-00420) is a spectrum-selective multikinase inhibitor that targets cell proliferation, angiogenesis, and immunomodulatory pathways by inhibiting Aurora A/B and JAK involved in cytokine signalling, and RTKs involved in angiogenesis (FGFRs and VEGFRs). |
